http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Priyanka Srivastava,Manish Naja,T. R. Seshadri,Hema Joshi,U. C. Dumka,Mukunda M. Gogoi,S. Suresh Babu 한국기상학회 2022 Asia-Pacific Journal of Atmospheric Sciences Vol.58 No.1
Accurate estimation of black carbon (BC) from the widely used optical attenuation technique is important for the reliable assessment of their climatic impact. The optical instruments use Mass Absorption Cross-section (MAC) for converting light attenuation records to BC mass concentrations and Aethalometer is a widely used optical instrument for BC estimation. Several studies have shown large variability inMAC values. It is thus necessary to examine the accuracy and consistency ofMAC values obtained using Aethalometer over distinct geographic locations and seasons. In the present study, MAC values are derived using simultaneous observations (2014–2017) from an EC-OC analyzer and an Aethalometer (AE-42) over a high altitude central Himalayan site at Nainital (29.4oN, 79.5oE, 1958 a.m.s.l). The observations reveal that the annual mean value of MAC (5.03 ± 0.03 m2g− 1 at 880nm) is significantly lower than the constant value used by the manufacturer (16.6 m2g− 1 at 880nm). The estimated MAC values also showed significant seasonal variation, spanning over a range from 3.7 to 6.6 m2g− 1. It is found that the seasonal variability of elemental carbon (EC), air mass variation and meteorological parameters play an important role in the changes in MAC values over this region. Multi-wavelength determination of MAC shows the contribution of absorption by species other than EC at shorter wavelengths.MAC does not show a clear diurnal variation, unlike EC and absorption coefficient. The slope of EC vs. corrected equivalent black carbon (eBC) showed a significant improvement during all seasons when compared with uncorrected eBC. This lends credibility to the fact that the use of site-specific MAC leads to more reliable estimates of eBC over the central Himalayan region. It is found that, instead of using the site specific MAC value, had we used the one supplied by the instrument, we would have underestimated the radiative forcing by about 7.8Wm− 2 which amounts to a reduction by 24 %.
HIV/AIDS-related lymphoma: perspective from a regional cancer center in India
A.H. Rudresha,Pravin Ashok Khandare,D. Lokanatha,Abraham Jacob Linu,M.C. Suresh Babu,K.N. Lokesh,L.K. Rajeev,Carol Saldanha Smitha,Vaibhav Baburao Amale,C.S. Premalata,Mulchandani Nikita 대한혈액학회 2019 Blood Research Vol.54 No.3
BackgroundIndia has the third largest population of people living with HIV/AIDS (PLHA). Lymphoma is the second most common malignancy among PLHA. However, data are lacking regard-ing HIV/AIDS-related lymphoma (ARL) in India. This study evaluated the epidemiology and clinical outcomes of ARL from a regional cancer center in India.MethodsThis retrospective analysis included cases of ARL between March 2011 and September 2017. Data were obtained from patient record files for the assessment of epidemiology and clinical outcomes. Statistical analysis was performed using GraphPad Prism 6. Comparisons of subtype-specific survivals were performed using log-rank tests.ResultsOf 1,226 lymphoma cases, 80 (6.5%) were ARL. Details were available for 70 patients. The median age at diagnosis was 40.5 (9‒74) years with a male:female ratio of 2:1. AIDS-defining lymphomas (ADL) constituted 78.6% of cases, while 21.4% had non-AIDS defining lymphoma (NADL). The mean CD4 counts were 193.15±92.85 and 301.93±107.95 cells/L, respectively (t-test; P=0.0002). Extranodal involvement was present in 55.7%, B symptoms were reported in 60%, and lactate dehydrogenase (LDH) was elevated in 64.3% of patients. The median overall survival times were 6 months for plasmablastic lymphoma (PBL), 23 months for diffuse large B-cell lymphoma (DLBCL), and was not reached for Hodgkin’s lymphoma (log-rank test; P=0.0011). Other histo-logical subtype cases were too few to draw meaningful survival outcomes.ConclusionARL is a heterogeneous disease. Histologic subtype is a major determinant of the clinical outcome. ADL has significantly lower CD4 counts than those of NADL. There is an urgent and unmet need for uniform management guidelines for improving outcomes in this un-der-represented patient population.